In a SINTEF lab in Norway, a short, synthetic DNA molecule helped every treated human cell survive a chemical stress that killed about 40% of untreated cells. The result is an early clue in research on Parkinson’s disease—not evidence that a treatment is ready for people.
The work builds on a 2021 discovery by researchers at Oslo University Hospital. They found that switching off a particular gene in the roundworm C. elegans protected a type of nerve cell from age-related damage. The same types of nerve cells are affected in people with Parkinson’s. The gene makes an enzyme involved in repairing damaged DNA, but experiments suggest the enzyme may also leave cells’ mitochondria—their energy-producing structures—more vulnerable to oxidative stress, a kind of cell damage linked to Parkinson’s.
Researchers at SINTEF, a Norwegian research organization, are now testing ways to lower production of that enzyme. Their candidate is an antisense oligonucleotide, or ASO: a short synthetic DNA segment designed to reduce the amount of a particular protein a cell makes. It works by targeting messenger RNA, the temporary copy of a gene’s instructions, rather than altering the gene itself.
Artem Komissarov, a research scientist in SINTEF’s Biotechnology and Nanomedicine department, compares the approach to removing a recipe copy instead of taking a book out of a library. It also differs from an mRNA vaccine: rather than supplying instructions for a cell to make a protein, the ASO aims to destroy some of the instructions already made. Komissarov says this could act like a dimmer switch, lowering protein production instead of turning a gene fully on or off.
In the cell experiment, researchers exposed HEK293 cells—a line commonly used in lab research—to MPP+, a substance used to disrupt mitochondria and create oxidative stress in experimental Parkinson’s models. About 40% of cells exposed to MPP+ alone died. When researchers also added an ASO candidate, all the cells survived. The test was not done on nerve cells, and it did not involve animals or people, so it cannot show whether the approach would prevent or treat Parkinson’s in patients.
SINTEF used a lab platform with robots to test many candidates in parallel. The researchers found several ASO sequences that reduced expression of the target gene by around 70%. They also examined toxicity at different concentrations. The source account says toxicity was assessed but does not give a final safety finding, so more work is needed to learn whether reducing the enzyme can protect cells without causing unwanted effects.
The findings offer a promising starting point, especially because brain mitochondria use large amounts of oxygen, as SINTEF senior researcher Torkild Visnes noted. The next challenge is to find the right degree of gene suppression and test whether the protection holds in more relevant models. For now, the result is a carefully bounded step: a small DNA-based tool protected cells in a dish, opening a path for further Parkinson’s research.
